Stock Quote
Repros Therapeutics Inc. (RPRX.W) (NASD ADF)
$0.72
9:55am EST
+0.00%
$0.72
$0.72
500
$0.72
$0.72
$13.94
$0.65
-0.02
781,219
RPRX.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Masterson, Nola | Chairman of the Board | -- |
| Podolski, Joseph | President, Chief Executive Officer, Director | 703,539 |
| Van As, Andre | Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs | 399,667 |
Profile
Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of... Full Description
Company Address
Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands TX 77380
P: +1281.7193400
F: +1281.7193446
2408 Timberloch Place
Suite B-7
The Woodlands TX 77380
P: +1281.7193400
F: +1281.7193446
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Schering-Plough Corporation | -- | -- |
| Solvay S.A. | €71.92 | +1.25 |
| Auxilium Pharmaceuticals, Inc. | $35.04 | +0.11 |
| RPRX.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 188.65 | 29.90 |
| ROI(TTM) | -452.83 | 2.35 |
| ROE(TTM) | -452.83 | 3.59 |
| Consensus Recommendation | Underperform |
|---|---|
| EPS Est. (Current Period) | -0.35 |
| EPS Est. (Current Year) | -2.10 |
| Total Revenue | $0.00M |
| Net Income | $-8.89M |
| EPS | $-0.59 |
